Advertisement

Topics

Latest "NanoVibronix Commence Trial Anti Aging Device Collaboration with" News Stories

17:33 EST 17th February 2019 | BioPortfolio

Here are the most relevant search results for "NanoVibronix Commence Trial Anti Aging Device Collaboration with" found in our extensive news archives from over 250 global news sources.

More Information about NanoVibronix Commence Trial Anti Aging Device Collaboration with on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about NanoVibronix Commence Trial Anti Aging Device Collaboration with for you to read. Along with our medical data and news we also list NanoVibronix Commence Trial Anti Aging Device Collaboration with Clinical Trials, which are updated daily. BioPortfolio also has a large database of NanoVibronix Commence Trial Anti Aging Device Collaboration with Companies for you to search.

Showing "NanoVibronix Commence Trial Anti Aging Device Collaboration with" News Articles 1–25 of 18,000+

Sunday 17th February 2019

. @Novartis Creates “Inflection Point” for @AbCelleraBio with 10-Target Antibody Collaboration: http://ow.ly/8PJy30nHIw7 pic.twitter.com/htE9oB1etR

. @Novartis Creates “Inflection Point” for @AbCelleraBio with 10-Target Antibody Collaboration: http://ow.ly/8PJy30nHIw7  pic.twitter.com/htE9oB1etR


Pembrolizumab Before and After Resection Boosts Glioblastoma Outcomes (CME/CE)

(MedPage Today) -- "Timing matters" for anti-PD-1 immunotherapy, study suggests

Saturday 16th February 2019

CheckMate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma

Prof Nizar Tannir speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about a thirty month follow up from the CheckMate 214 trial. He begins by outlining the preliminary data for the trial, and then how the follow up data compared with...


#GU19 Anti-PD-(L)1 + TKI combo setting new SoC in 1L mRCC, full data showdown in NEJM $MRK Keynote-426 https://www.nejm.org/doi/full/10.1056/NEJMoa1816714?query=featured_home … $PFE Javelin Renal 101 https://www.nejm.org/doi/full/10.1056/NEJMoa18160

#GU19 Anti-PD-(L)1 + TKI combo setting new SoC in 1L mRCC, full data showdown in NEJM $MRK Keynote-426 https://www.nejm.org/doi/full/10.1056/NEJMoa1816714?query=featured_home … $PFE Javelin Renal 101 https://www.nejm.org/doi/full/10.1056/NEJMoa1816047?query=featured_home …

KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) Reduced Risk of Death by Nearly Half Compared to Sunitinib as First-Line Treatment for Advanced Renal Cell Carcinoma (RCC)

Results from Phase 3 KEYNOTE-426 Study Presented Today at the 2019 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine Also Showed Risk of Progression or Death Reduced by 31 Percent Data Consistent Across all IMDC Risk Groups and Regardless of PD-L1 Expression Merck (NYSE: MRK), known as MSD ou...

Trump science adviser calls for more collaboration between industry and government

. @GileadSciences’ Lead Liver Disease Candidate Selonsertib Fails Phase III Trial in NASH: http://ow.ly/WWoS30nFK5S pic.twitter.com/g3nPSuGjll

. @GileadSciences’ Lead Liver Disease Candidate Selonsertib Fails Phase III Trial in NASH: http://ow.ly/WWoS30nFK5S  pic.twitter.com/g3nPSuGjll

$AVEO Announces Oral Presentation of TIVO-3 Trial Topline Results at the ASCO #GU19 https://www.businesswire.com/news/home/20190216005008/en/AVEO-Oncology-Announces-Oral-Presentation-TIVO-3-Trial …

$AVEO Announces Oral Presentation of TIVO-3 Trial Topline Results at the ASCO #GU19 https://www.businesswire.com/news/home/20190216005008/en/AVEO-Oncology-Announces-Oral-Presentation-TIVO-3-Trial …

AVEO Oncology Announces Oral Presentation of TIVO-3 Trial Topline Results at the 2019 ASCO Genitourinary Cancers Symposium

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC). The data were presented by Brian Rini, MD, Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and Di...

A randomised controlled trial to evaluate the plaque removal efficacy of sodium bicarbonate dentifrices in a single brushing clinical model

Latest GEN List -- Unlucky 13: Top Clinical Trial Failures of 2018 -- http://ow.ly/Y4Bk30nERpI pic.twitter.com/4c5tg40LKU

Latest GEN List -- Unlucky 13: Top Clinical Trial Failures of 2018 -- http://ow.ly/Y4Bk30nERpI  pic.twitter.com/4c5tg40LKU

Outcomes Better With Arthroscopy for Femoroacetabular Impingement

Arthroscopic hip surgery results in better outcomes than physiotherapy and activity modification in patients with symptomatic femoroacetabular impingement (FAI), according to a new clinical trial, but researchers still urge caution. Reuters Health Information

SILCSKIN™ DECOLLETTE PAD AWARDED WINNER of LNE & SPA’S Best Product in Neck and Decollete Category Two Years in a Row

LOS ANGELES (PRWEB) February 15, 2019 SilcSkin – silicone anti-wrinkle pad pioneer and creator of the original and #1 selling Decollette pad – was awarded LNE & Spa’s Best Product for 2019 in the Neck and Decolleté category for the second time. The Decollette Pad was selected based o...

Are you interested in biotechnology news ?

Read the latest on pharma/biotech news, Clinical Trial Results, FDA Calendar, Top Gainers, Recalls, Food Alert and more on RTTNews Biotechnology.

News digest – HPV stigma, ultra-processed foods, ‘simple’ cancer blood test and why measles isn’t a cancer cure

Science blog Stigma around HPV infection causes concern Misunderstanding and perceived stigma around the human papillomavirus (HPV) infection is concerningly high and could put women off cervical screening, reports the Independent and others. The results

Friday 15th February 2019

Company Profile for Novus Therapeutics, Inc.

Novus Therapeutics, Inc. (“Novus”) is a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (“ENT”). Novus has two technologies, each that has the potential to be developed for multiple ENT indications. Novus’ lead product candidate (OP0201) is a surfactant-based, drug-device co...

STREAM trial: Enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk PSA recurrent PC

Prof Andrew Armstrong speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about the STREAM trial investigating the use of enzalutamide and androgen deprivation therapy (ADT) with salvage radiation in patients with high-risk PSA recurrent...

Analysis of acute toxicity from PACE-B: Comparing SBRT to CFMHRT for localised prostate cancer

Dr Nicholas van As speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about analysis of acute toxicity from the randomised phase III PACE-B trial comparing tereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately...

Antibe Therapeutics Reports Q3 2019 Interim Financial and Operating Results

Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, February 15th for the fiscal quarter ended December 31, 2018. The Company’s unaudited fiscal Q3 2019 condensed interim consolidated financial statements and MD&A are available on SEDAR. About Antib...

Drug combination may become new standard treatment for advanced kidney cancer

(Dana-Farber Cancer Institute) A combination of two drugs -- one of them an immunotherapy agent -- could become a new standard, first-line treatment for patients with metastatic kidney cancer, says an investigator from Dana-Farber Cancer Institute, reporting results from a phase 3 clinical trial.

Avapritinib receives Phase III clinical trial approval for GIST in China

SUZHOU, China, Feb. 15, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone") today announced that the National Medical Products Administration (NMPA) recently approved a Phase III clinical trial in China for its partnered drug candidate avapritinib as a third-line treatment against KIT-driven gastrointestinal stromal tumors (GIST). The study will be part of the global VOYAGER Phase II...

MUSC researchers discover new mechanism for a class of anti-cancer drugs

Researchers at the Medical University of South Carolina reveal a novel binding site for a class of anti-cancer drugs known as E1 inhibitors. This finding could lead to the design of more efficient E1 inhibitors.

New technique using patients' own modified cells could help treat Crohn's disease

A new technique using patients' own modified cells to treat Crohn's disease has been proven to be effective in experiments using human cells, with a clinical trial of the treatment expected to start in the next six months.

Early-stage trial shows promising results for Opdivo, bempegaldesleukin combination in first-line urothelial carcinoma https://www.firstwordpharma.com/node/1625554?tsid=28®ion_id=6 …

Early-stage trial shows promising results for Opdivo, bempegaldesleukin combination in first-line urothelial carcinoma https://www.firstwordpharma.com/node/1625554?tsid=28&region_id=6 …

Medical device company raises $27.8M for AI-enabled blood tests


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks